Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Elizabeth S. Appleton"'
Publikováno v:
Clinical Case Reports
Key Clinical Message We present a rare case of a patient with delayed gastric emptying, gastric phytobezoar formation, and osteosclerotic bone lesions as an atypical association with multiple myeloma. Associated gastric features in myeloma, which inc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::91a5c18d33ff820eae98d5a5002ff3e2
http://europepmc.org/articles/PMC5582312
http://europepmc.org/articles/PMC5582312
Autor:
Susan C Short, Elizabeth S. Appleton, Gemma Migneco, David Taggart, Simon Thomson, Gerard J. Nuovo, Lucy F. Stead, Sergio A. Quezada, Samantha J. Turnbull, Adel Samson, Philip van Hille, Richard G. Vile, Julia V. Cockle, D. Beirne, Fiona Collinson, Fiona Errington-Mais, Karen Scott, Peter Selby, Euan S. Polson, Kevin J. Harrington, Erica B. Wilson, Heiko Wurdak, Martin Fuller, Stephen Griffin, Jill Thompson, Timothy Kottke, Hardev Pandha, Gnanamurthy Sivakumar, Chris Twelves, Ailsa Rose, Christy Ralph, Andrew Furness, Elizabeth Ilett, Robert Corns, Emma West, D. Alan Anthoney, Matthew C. Coffey, Ryan K. Mathew, Alan Melcher
Immune checkpoint inhibitors, including those targeting programmed cell death protein 1 (PD-1), are reshaping cancer therapeutic strategies. Evidence suggests, however, that tumor response and patient survival are determined by tumor programmed death
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f4899fce1ad145ea879d424f0b5ba845
Autor:
Samantha J. Turnbull, Kevin J. Harrington, Christy Ralph, Elizabeth S. Appleton, Alan Melcher, Emma West, Karen Scott, Hardev Pandha
Publikováno v:
Expert Opinion on Biological Therapy. 15:1517-1530
Metastatic melanoma continues to present a significant therapeutic challenge, with an incidence rate rising faster than that of any other cancer. The last 5 years have seen a revolution in the development of new treatments for advanced melanoma, with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::806cec183b80415542aba56c541963ca
https://doi.org/10.1517/14712598.2015.1084280
https://doi.org/10.1517/14712598.2015.1084280
Autor:
Ralph C. Anth, G. SivaKumar, Julia V. Cockle, Adel Jebar, G. Nuovo, Martin Fuller, R. Corns, Emma West, David Taggart, Elizabeth S. Appleton, Fiona Errington, Matthew C. Coffey, P. Van Hille, Ailsa Rose, Ryan K. Mathew, Karen Scott, Stephen Griffin, Gemma Migneco, Simon Thomson
INTRODUCTION: Oncolytic viruses preferentially replicate in cancer cells and kill them through direct cytotoxicity and/or immune mediated cell destruction. REOLYSIN® is a proprietary isolate of reovirus type 3 Dearing. In previous trials using intra
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f4bddeda69e86c87a10dc12b310a4e77
https://europepmc.org/articles/PMC4657649/
https://europepmc.org/articles/PMC4657649/